HEAD AND NECK SQUAMOUS CELL CARCINOMA

This early-stage study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (breast, ovarian, lung, and others) that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of tumor sh…

This study tests whether giving two drugs—nivolumab and an anti-IL-8 antibody—before surgery is safe and feasible for people with head and neck cancer. About 24 participants will receive the combination before their operation. The goal is to see if this approach can help shrink t…

This study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemo alone for people with head and neck cancer that has spread or come back. About 100 adults who h…

This study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than the standard chemotherapy drug cisplatin with radiation for patients with a certain type of head and neck cancer (p16-positive). About 126 adults with advanced or in…

This early-stage trial tests a combination of two drugs (naptumomab estafenatox and durvalumab) in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and see if the combination can shrink tumors. About 120 …

This study tests whether giving a short course of radiation plus an immunotherapy drug (pembrolizumab) before surgery can shrink advanced head and neck cancers more effectively. About 28 adults with stage III or IV HPV-negative head and neck cancer will receive this neoadjuvant t…

This study tests whether combining three different medicines (BI 770371, pembrolizumab, and cetuximab) can shrink tumors better than pembrolizumab alone in adults with advanced head and neck cancer. Participants are randomly assigned to one of three treatment groups and receive i…

This early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…

This early-stage study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The study aims to find a safe dose and see if the drug can sh…

This early-phase study tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation for people with advanced head and neck cancer that has spread to nearby tissues or lymph nodes. The main goal is to find the safest dose and check for side…

This study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 122 participants will be randomly assigned to receive either the drug combo or chemo alone for thr…

This study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…

This study tests a new drug called SI-B001 combined with paclitaxel in 42 adults with recurrent or metastatic head and neck squamous cell carcinoma that has worsened after standard treatments. The goal is to see if the combination can shrink tumors and control the disease. Partic…

This study tests whether adding other drugs to tislelizumab helps shrink or control head and neck cancer that has returned or spread. About 160 adults with certain types of this cancer will receive the treatment as their first therapy for advanced disease. The goal is to see if t…

This study tests two different doses of the experimental drug FID-007 combined with cetuximab in people with advanced head and neck cancer that has come back or spread. About 46 adults whose cancer worsened after immunotherapy will be randomly assigned to one of two dosing schedu…

This study tests a three-step treatment plan for people with a type of head and neck cancer not caused by HPV. First, patients take a drug called palbociclib before standard chemoradiation, then receive chemoradiation, and finally take palbociclib again after treatment. The goal …

This study tests two ways to treat advanced larynx or hypopharynx cancer while trying to avoid removing the voice box. One group gets chemotherapy before radiation, the other gets chemo during radiation. The goal is to see which approach better preserves larynx function two years…

This study compares two chemotherapy drug combinations in 128 people with advanced head and neck cancer that hasn't been treated yet. The goal is to find out which combination helps patients live longer without the cancer growing back. Researchers will also track side effects to …

This study tests an experimental drug called NT219 combined with either pembrolizumab or cetuximab in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors. About 29 adults with incurable head and neck squamous cell…

This early-stage trial tests a vaccine (p53MVA) plus the immunotherapy drug pembrolizumab in 11 adults with advanced solid tumors that have not responded to other treatments. The vaccine trains the immune system to target cancer cells with a faulty p53 gene, while pembrolizumab h…

This study tests a new drug, SI-B001, in 11 adults with advanced head and neck cancer that returned or spread after standard treatments. The goal is to see if the drug can shrink tumors or slow the disease. Participants receive the drug alone, and researchers monitor safety and h…

This study is for people with certain lung, liver, or head/neck cancers that can be removed with surgery. Participants receive an investigational drug called cemiplimab, sometimes combined with another drug called fianlimab, before their operation. The goal is to see if these dru…

This early-phase study tests whether giving two immune-boosting drugs (LVGN7409 and a PD-1 inhibitor) before surgery can safely help the body fight HPV-negative head and neck cancer. About 27 adults with resectable tumors will receive the combination, then undergo surgery. The ma…

This study tests a new pill called IPN01194 in adults with advanced solid tumors (cancers that have spread). The goal is to find the right dose and check if it is safe and shrinks tumors. About 36 people with melanoma, colorectal, pancreatic, or head and neck cancers will take th…

This study tests a new drug, ARRY-614, combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds the safest dose, and the second part checks if the comb…

This study aimed to test a new combination of two drugs (TTI-101 and pembrolizumab) for people with advanced head and neck cancer that had come back or spread. The goal was to see if the combo was safe and could shrink tumors. However, the study was withdrawn before any participa…

This study tests whether combining an HPV DNA vaccine with immunotherapy drugs can shrink advanced head and neck cancers caused by HPV types 16 or 18 before surgery. About 56 adults with resectable tumors will receive one of three treatment combinations. The main goal is to see i…

This study looks at adults with head and neck cancer that has spread to 1-3 other spots (oligometastases). It compares two treatments: stereotactic radiotherapy alone versus radiotherapy plus chemotherapy. The goal is to see which approach helps people live longer with a good qua…

This study tests a combination of three drugs (cisplatin, nab-paclitaxel, and cetuximab) in 74 people with head and neck cancer that cannot be cured. The goal is to see if this mix works better and causes fewer side effects than the standard treatment. Participants must have canc…

This study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab)…

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) in a single shot. It enrolls 18 adults with various advanced solid tumors that have spread or come back. The main goal is to find the safest dose and underst…

This early-phase study tests a new drug (INCB081776) combined with standard radiation and an immunotherapy (pembrolizumab) in people with head and neck cancer that has spread or come back. The goal is to see if the combination is safe and helps control the disease. About 10 parti…

This early-stage trial tests a new drug called IMT-009 in about 67 people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. Researchers will also check if the drug can shrin…

This study tests a new combination of immune-boosting drugs for people with advanced solid tumors (like lung, bladder, or skin cancer) whose cancer stopped responding to standard immunotherapy. About 40 participants will receive a novel drug called NAI along with other therapies …

This study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The goal is to find safe doses and check for side effects. About 72 participants will receive increa…

This early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors (such as liver, pancreatic, breast, and ovarian cancers). The goal is to see if the drug is safe and can shrink tumors. Participants receive the drug by IV, alone or w…

This early-phase study tests a new drug (sEphB4-HSA) combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and check for side effects. About 61 …

This study tests whether adding metformin (a common diabetes drug) to pembrolizumab (an immunotherapy) can help shrink tumors in people with advanced head and neck cancer that has spread. About 21 participants whose cancer cannot be cured with surgery or radiation will receive th…

This study looks at whether adding lenvatinib to pembrolizumab (a type of immunotherapy) after standard chemoradiation can help prevent head and neck cancer from coming back. About 50 adults with advanced, PD-L1 positive head and neck cancer will take part. The goal is to see if …

This study is testing a new imaging device called MSOT that uses light and sound to create detailed pictures of neck lymph nodes in people with head and neck cancer. The goal is to see if it can more accurately find cancer that has spread and also detect tissue damage from radiat…

This study explores whether creating a 3D map of a patient's tumor after surgery helps doctors plan radiation therapy more precisely. The goal is to better target cancer cells while protecting nearby healthy organs. About 13 adults with head and neck cancer will have their standa…

This study looks at whether a more intensive follow-up schedule after treatment for head and neck cancer helps people live longer compared to a standard schedule. It involves 197 smokers or heavy drinkers over age 35 who are cancer-free 2-4 months after treatment. The goal is to …

This study aimed to test a new test called OncoPrism-HNSCC to see if it could predict how well immunotherapy would work in people with head and neck cancer. Researchers planned to analyze tumor samples taken before treatment. However, the study was withdrawn before any participan…